Jay B. Lichter - 26 Jun 2024 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Source evidence 5 source fields
Form type
4
Accepted by SEC
28 Jun 2024, 16:30:51 UTC
Previous filing
05 Jun 2024
Next filing
24 Oct 2024
SEC filing
View on sec.gov
Reporting owner 1 detail
Reporting owner signature
/s/ Maria Dobek, Attorney-in-Fact

Key filing fact

Jay B. Lichter filed Form 4 for Janux Therapeutics, Inc. (JANX) on 28 Jun 2024.

Key facts

  • This page summarizes Jay B. Lichter's Form 4 filing for Janux Therapeutics, Inc. (JANX).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 28 Jun 2024, 16:30.

Change

  • Previous filing in this sequence was filed on 05 Jun 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

JANX transaction

Common Stock

Award

Transaction value
$0
Shares
+2,500
Change %
+55%
Price
$0.000000
Shares after
7,083
Date
26 Jun 2024
Ownership
Direct
Footnotes
F1
JANX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
3,271,216
Date
26 Jun 2024
Ownership
By Avalon Ventures XI, L.P.
Footnotes
F2
JANX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
633,673
Date
26 Jun 2024
Ownership
By Avalon BioVentures I, LP
Footnotes
F3
JANX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
3,340,018
Date
26 Jun 2024
Ownership
By Avalon BioVentures SPV I, L.P.
Footnotes
F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

JANX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+8,350
Change %
Price
$0.000000
Shares after
8,350
Date
26 Jun 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
8,350
Exercise price
$39.80
Footnotes
F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 26, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.

Footnote F2

The shares are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to have voting and investment power with respect to the shares held by Avalon Ventures. The Reporting Person is a managing member of Avalon XI GP and shares voting and investment power with respect to the shares held by Avalon Ventures. The Reporting Person disclaims beneficial ownership of all shares held by Avalon Ventures except to the extent of his actual pecuniary interest therein, if any.

Footnote F3

The shares are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is a general partner of ABV I and may be deemed to have voting and investment power with respect to the shares held by ABV I and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a managing member of ABV GP and shares voting and investment power with respect to the shares held by ABV I. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any.

Footnote F4

The shares are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a managing member of ABV SPV GP and shares voting and investment power with respect to the shares held by ABV SPV. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any.

Footnote F5

The shares subject to the option will vest in equal monthly installments over the 12 months following June 26, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .